Literature DB >> 10549796

Mapping biochemistry to metabolism: FDG-PET and amyloid burden in Alzheimer's disease.

M S Mega1, T Chu, J C Mazziotta, K H Trivedi, P M Thompson, A Shah, G Cole, S A Frautschy, A W Toga.   

Abstract

We evaluated the relationship between amyloid-beta protein (A beta) concentration and the metabolic abnormality in an Alzheimer's disease (AD) patient as measured by [18F]fluorodeoxyglucose positron emission tomography (FDG-PET). Across most regions there were significant inverse correlations among FDG-PET intensity values and both insoluble. The temporal lobe samples showed no significant correlation between FDG-PET values and A beta deposition. Findings support A beta as contributing to the hypometabolism in regions of the AD brain that are still relatively viable metabolically; those regions with chronic pathologic damage, such as temporal cortex, may have other factors that contribute to metabolic deficits.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10549796     DOI： 10.1097/00001756-199909290-00007

Source DB:  PubMed          Journal:  Neuroreport        ISSN： 0959-4965            Impact factor:   1.837


  12 in total

Review 1.  The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias.

Authors:  Victor L Villemagne; Michelle T Fodero-Tavoletti; Kerryn E Pike; Roberto Cappai; Colin L Masters; Christopher C Rowe
Journal:  Mol Neurobiol       Date:  2008-08-09       Impact factor: 5.590

2.  Neurological imaging: statistics behind the pictures.

Authors:  Ivo D Dinov
Journal:  Imaging Med       Date:  2011-08-01

3.  Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study.

Authors:  Serge A R B Rombouts; Frederik Barkhof; Rutger Goekoop; Cornelis J Stam; Philip Scheltens
Journal:  Hum Brain Mapp       Date:  2005-12       Impact factor: 5.038

4.  Relations between hypometabolism in the posterior association neocortex and hippocampal atrophy in Alzheimer's disease: a PET/MRI correlative study.

Authors:  K Meguro; C LeMestric; B Landeau; B Desgranges; F Eustache; J C Baron
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-09       Impact factor: 10.154

Review 5.  Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease.

Authors:  Bradford C Dickerson; Reisa A Sperling
Journal:  NeuroRx       Date:  2005-04

6.  Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI).

Authors:  Susanne G Mueller; Michael W Weiner; Leon J Thal; Ronald C Petersen; Clifford R Jack; William Jagust; John Q Trojanowski; Arthur W Toga; Laurel Beckett
Journal:  Alzheimers Dement       Date:  2005-07       Impact factor: 21.566

7.  Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve.

Authors:  Ann D Cohen; Julie C Price; Lisa A Weissfeld; Jeffrey James; Bedda L Rosario; Wenzhu Bi; Robert D Nebes; Judith A Saxton; Beth E Snitz; Howard A Aizenstein; David A Wolk; Steven T Dekosky; Chester A Mathis; William E Klunk
Journal:  J Neurosci       Date:  2009-11-25       Impact factor: 6.167

8.  Disease-Specific Probabilistic Brain Atlases.

Authors:  Paul Thompson; Michael S Mega; Arthur W Toga
Journal:  Proc IEEE Comput Soc Conf Comput Vis Pattern Recognit       Date:  2000-06-11

9.  Model-free group analysis shows altered BOLD FMRI networks in dementia.

Authors:  Serge A R B Rombouts; Jessica S Damoiseaux; Rutger Goekoop; Frederik Barkhof; Philip Scheltens; Stephen M Smith; Christian F Beckmann
Journal:  Hum Brain Mapp       Date:  2009-01       Impact factor: 5.038

10.  β-Amyloid is associated with aberrant metabolic connectivity in subjects with mild cognitive impairment.

Authors:  Felix Carbonell; Arnaud Charil; Alex P Zijdenbos; Alan C Evans; Barry J Bedell
Journal:  J Cereb Blood Flow Metab       Date:  2014-04-16       Impact factor: 6.200
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.